Publication

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

Swen, J. J., Nijenhuis, M., van Rhenen, M., de Boer-Veger, N. J., Buunk, A-M., Houwink, E. J. F., Mulder, H., Rongen, G. A., van Schaik, R. H. N., van der Weide, J., Wilffert, B., Deneer, V. H. M., Guchelaar, H-J. & Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP), May-2018, In : Clinical Pharmacology & Therapeutics. 103, 5, p. 795-801 7 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • Pharmac ogenetic Information in ClinicalGuidelines: The European Perspective

    Final publisher's version, 125 KB, PDF-document

DOI

  • Jesse J Swen
  • Marga Nijenhuis
  • Mandy van Rhenen
  • Nienke J de Boer-Veger
  • Anne-Marie Buunk
  • Elisa J F Houwink
  • Hans Mulder
  • Gerard A Rongen
  • Ron H N van Schaik
  • Jan van der Weide
  • Bob Wilffert
  • Vera H M Deneer
  • Henk-Jan Guchelaar
  • Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP)

Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).(1-3) In addition, patients are willing to consent to participate in PGx implementation studies.(4) However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test.(1,2) Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients.(5,6)

Original languageEnglish
Pages (from-to)795-801
Number of pages7
JournalClinical Pharmacology & Therapeutics
Volume103
Issue number5
Early online date20-Feb-2018
Publication statusPublished - May-2018

    Keywords

  • DECISION-SUPPORT, PREEMPTIVE PHARMACOGENOMICS, NATIONWIDE SURVEY, IMPLEMENTATION, MEDICINE, NETWORK, CYP2D6, MODEL, POLYPHARMACY, CONSORTIUM

View graph of relations

ID: 54918169